##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 9 (2025)

Treatment patterns and clinical outcomes in stage III non-small-cell lung cancer: a long-term institutional experience in Switzerland

Cite this as:
Swiss Med Wkly. 2025;155:4522
Published
22.09.2025

Summary

STUDY AIM: Treatment of stage III non-small-cell lung cancer (NSCLC) has evolved rapidly in recent years. To improve our understanding of real-world outcomes in Switzerland, we report on our institutional experience at an academic lung cancer centre and describe treatment patterns and clinical outcomes over a multi-year period.

METHODS: Patients diagnosed with stage III NSCLC between 2013 and 2023 were included in an ethics-approved institutional database. Based on tumour board decisions, the initial treatment strategy was defined for each patient. Overall and progression-free survival were calculated using the Kaplan-Meier method. A multivariate Cox regression analysis was performed to study the impact of different factors on clinical outcomes.

RESULTS: A total of 315 patients with stage III NSCLC were included. Patients were a median of 68 years old, and two-thirds were male. The most common stage at diagnosis was IIIA (56%), followed by stage IIIB (36%) and IIIC (8%). A curative treatment approach was pursued in 88% of patients, and over 90% of these received definitive local treatment (surgery and/or radiotherapy). Rates of 1-year overall and progression-free survival improved from 64% and 47%, respectively, in 2013–2016, to 82% and 70% in 2020–2023. However, 49% of patients developed locoregional and/or distant recurrence. Results of the multivariate analysis are presented in the manuscript.

CONCLUSIONS: Almost 90% of patients with stage III NSCLC underwent treatment with curative intent, with rates of treatment adherence that compared favourably to the literature. Although survival outcomes appear to have improved in recent years, the rates of disease recurrence remain high, reflecting a need for further improvements.

References

  1. 1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. doi: https://doi.org/10.3322/caac.21834
  2. 2. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020 Aug;383(7):640–9. doi: https://doi.org/10.1056/NEJMoa1916623
  3. 3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007 Aug;2(8):706–14. doi: https://doi.org/10.1097/JTO.0b013e31812f3c1a
  4. 4. Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al.; Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015 Aug;26(8):1573–88. doi: https://doi.org/10.1093/annonc/mdv187
  5. 5. Finazzi T, Schneiders FL, Senan S. Developments in radiation techniques for thoracic malignancies. Eur Respir Rev. 2021 May;30(160):200224. doi: https://doi.org/10.1183/16000617.0224-2020
  6. 6. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr;40(12):1301–11. doi: https://doi.org/10.1200/JCO.21.01308
  7. 7. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al.; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May;386(21):1973–85. doi: https://doi.org/10.1056/NEJMoa2202170
  8. 8. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al.; KEYNOTE-671 Investigators. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Aug;389(6):491–503. doi: https://doi.org/10.1056/NEJMoa2302983
  9. 9. Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al.; AEGEAN Investigators. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Nov;389(18):1672–84. doi: https://doi.org/10.1056/NEJMoa2304875
  10. 10. Adizie JB, Khakwani A, Beckett P, Navani N, West D, Woolhouse I, et al. Stage III Non-small Cell Lung Cancer Management in England. Clin Oncol (R Coll Radiol). 2019 Oct;31(10):688–96. doi: https://doi.org/10.1016/j.clon.2019.07.020
  11. 11. Evison M, Edwards J, McDonald F, Popat S. Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice. Clin Oncol (R Coll Radiol). 2020 Aug;32(8):527–36. doi: https://doi.org/10.1016/j.clon.2020.03.001
  12. 12. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al.; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul;28(January suppl_4):iv1–21. doi: https://doi.org/10.1093/annonc/mdx222
  13. 13. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al.; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Jan;11(1):39–51. doi: https://doi.org/10.1016/j.jtho.2015.09.009
  14. 14. Provencio M, Carcereny E, López Castro R, Calvo V, Rodríguez Abreu D, Cobo M, et al. Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study. Transl Lung Cancer Res. 2023 Oct;12(10):2113–28. doi: https://doi.org/10.21037/tlcr-23-176
  15. 15. Jazieh AR, Onal HC, Tan DS, Soo RA, Prabhash K, Kumar A, et al. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study. J Thorac Oncol. 2021 Oct;16(10):1733–44. doi: https://doi.org/10.1016/j.jtho.2021.05.003
  16. 16. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct;103(19):1452–60. doi: https://doi.org/10.1093/jnci/djr325
  17. 17. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb;16(2):187–99. doi: https://doi.org/10.1016/S1470-2045(14)71207-0
  18. 18. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: randomized Phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016 Mar;34(9):953–62. doi: https://doi.org/10.1200/JCO.2015.64.8824
  19. 19. Evison M; AstraZeneca UK Limited. The current treatment landscape in the UK for stage III NSCLC. Br J Cancer. 2020 Dec;123(S1 Suppl 1):3–9. doi: https://doi.org/10.1038/s41416-020-01069-z
  20. 20. Carrato A, Vergnenègre A, Thomas M, McBride K, Medina J, Cruciani G. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin. 2014 Mar;30(3):447–61. doi: https://doi.org/10.1185/03007995.2013.860372
  21. 21. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug;374(9687):379–86. doi: https://doi.org/10.1016/S0140-6736(09)60737-6
  22. 22. van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, et al.; European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007 Mar;99(6):442–50. doi: https://doi.org/10.1093/jnci/djk093
  23. 23. Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol. 2015 Dec;33(35):4194–201. doi: https://doi.org/10.1200/JCO.2015.62.6812
  24. 24. Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et al.; Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol. 2021 Sep;39(26):2872–80. doi: https://doi.org/10.1200/JCO.21.00276
  25. 25. Werner RS, Curioni-Fontecedro A, Mauti LA, Addeo A, Peters S, Frauenfelder T, et al.; SAKK. Lung Cancer in Switzerland. J Thorac Oncol. 2024 Mar;19(3):385–94. doi: https://doi.org/10.1016/j.jtho.2023.12.005
  26. 26. König D, Schär S, Vuong D, Guckenberger M, Furrer K, Opitz I, et al. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO Open. 2022 Apr;7(2):100455. doi: https://doi.org/10.1016/j.esmoop.2022.100455
  27. 27. Naidoo J, Antonia S, Wu YL, Cho BC, Thiyagarajah P, Mann H, et al. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. J Thorac Oncol. 2023 May;18(5):657–63. doi: https://doi.org/10.1016/j.jtho.2023.02.009
  28. 28. Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al.; LAURA Trial Investigators. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug;391(7):585–97. doi: https://doi.org/10.1056/NEJMoa2402614
  29. 29. Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al.; ALINA Investigators. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 Apr;390(14):1265–76. doi: https://doi.org/10.1056/NEJMoa2310532
  30. 30. Bouazza YB, Chiairi I, El Kharbouchi O, De Backer L, Vanhoutte G, Janssens A, et al. Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review. Lung Cancer. 2017 Nov;113:140–51. doi: https://doi.org/10.1016/j.lungcan.2017.09.011